Abstract: The present invention relates to a composition for treating prostate cancer and, more specifically, to a composition for treating prostate cancer, which contains a peptide derived from telomerase and is effective in inhibiting growth and metastasis of prostate cancer cells. In addition, the present invention provides a composition and method for treating prostate cancer, wherein, when prostate cancer is treated, docetaxel and the peptide derived from telomerase are co-administered, thereby having a synergetic therapeutic effect compared with administration alone. Particularly, the present invention provides a treatment method useful for patients who do not have a sufficient anticancer effect merely through administration of docetaxel alone and patients who have hormone resistance.

Abstract: The present specification relates to an anti-viral composition and, more particularly, to a composition that both is anti-viral and prevents and treats diseases associated with viruses, containing a peptide derived from a telomerase, thereby being effective in treating and preventing diseases associated with viruses and pathological symptoms caused by viruses. The peptide exhibits an effect of treating diseases associated with viruses by inhibiting the RNA replication of viruses, thereby being capable of providing a method that both is antiviral and prevents and treats diseases associated with viruses.

Abstract: A semiconductor device includes a semiconductor chip body having a surface on which a chip pad is disposed, a passivation layer covering the surface of the semiconductor chip body and providing a tapered hole revealing the chip pad, and a redistributed layer (RDL) structure disposed on the passivation layer. The RDL structure includes a first RDL interconnection portion spaced apart from the tapered hole and passing by the tapered hole and a second RDL overlapping pad portion configured to have a bottom portion contacting the revealed chip pad and configured to have a first side surface facing a side surface of the first RDL interconnection portion. A central portion of the first side surface of the second RDL overlapping pad portion extends toward the side surface of the first RDL interconnection portion such that the first side surface is curved.

Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising amino acid sequence of SEQ ID NO:1, a fragment of any one sequence of SEQ ID NO:1, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.

Abstract: A peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides is described. An anti-inflammatory composition comprising the above mentioned peptides is described. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.

Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, the peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.

Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 156, a fragment of any one sequence of SEQ ID NO: 1 to SEQ ID NO: 156, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.

Abstract: The present specification relates to a composition containing a peptide having effects of increasing telomerase activity and extending a telomere, and more specifically, to a composition containing a telomerase-derived peptide, thereby being effective for preventing, alleviating and treating diseases, caused by a decrease in telomerase activity or a reduction in telomere length, and symptoms caused by cell aging or damage. According to one aspect to the present invention, the peptide increases telomerase activity and is effective for extending a telomere, and thus a method for treating diseases induced by an abnormal decrease in telomerase activity and by the length reduction or loss of a telomere and alleviating symptoms caused thereby can be provided.

Abstract: A peptide with anti-inflammatory activity is described, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising those peptides can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.

Abstract: The present invention relates to a pharmaceutical composition for preventing and treating hearing loss. More particularly, the present invention relates to a composition including a telomerase-derived peptide, the composition being effective in the treatment and prevention of hearing loss due to an ototoxic drug. A peptide having a sequence of SEQ ID NO: 1, a peptide having 80% or more sequence homology to the sequence, or a fragment thereof, according to the present invention, has an excellent effect in the treatment and prevention of hearing loss due to an ototoxic drug.

Abstract: The present invention relates to a conjugate of cell penetrating peptide and an active ingredient; and its use. Specifically, a conjugate including a cell penetrating peptide which is a peptide comprising any one amino acid sequence of SEQ ID NO: 1 to SEQ ID NO: 156, a fragment of any one sequence of SEQ ID NO: 1 to SEQ ID NO: 156, or a peptide having above 80% homology with the above-mentioned sequence; and a composition comprising the same are disclosed.

Abstract: The present invention relates to methods of treating or preventing inflammation with a peptide having anti-inflammatory activity, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 101. According to the present invention, the peptide of SEQ ID NO: 101 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the method comprising administration of the peptide of this invention can be used in anti-inflammatory pharmaceutical or cosmetic applications, in turn, treating and preventing a variety of different types of inflammatory diseases.

Abstract: Peptides and compositions comprising the peptides, and more particularly, a peptide effective in anti-inflammation, anti-fibrosis, wound healing, and anti-cancer treatment, and a composition including the same are described. The peptides provided herein and the compositions comprising the peptides exhibit an effect of alleviating, preventing, or treating inflammation, fibrosis, wounds, and symptoms of diseases such as cancer including these symptoms, and thus may provide a method of preventing or treating associated diseases.

Abstract: Disclosed are: a composition for organ, tissue or cell transplantation, containing, as an active ingredient, a peptide comprising the amino acid sequence of SEQ ID NO: 1, a peptide having at least 80% sequence homology with the amino acid sequence, or a peptide which is a fragment thereof; a kit comprising the composition; or a method using the composition. By using the composition, the kit, or the method, the viability and/or function of an organ, tissue, or cell after transplantation are strengthened and an organ, tissue or cell isolated from a living body is preserved temporarily without damage.

Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises any one amino acid sequence of SEQ ID NO:1 to SEQ ID NO:161, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide that has at least one amino acid sequence of SEQ ID NO:1 to SEQ ID NO:161 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.

Abstract: A semiconductor device includes a semiconductor chip body having a surface on which a chip pad is disposed, a passivation layer covering the surface of the semiconductor chip body and providing a tapered hole revealing the chip pad, and a redistributed layer (RDL) structure disposed on the passivation layer. The RDL structure includes a first RDL interconnection portion spaced apart from the tapered hole and passing by the tapered hole and a second RDL overlapping pad portion configured to have a bottom portion contacting the revealed chip pad and configured to have a first side surface facing a side surface of the first RDL interconnection portion. A central portion of the first side surface of the second RDL overlapping pad portion extends toward the side surface of the first RDL interconnection portion such that the first side surface is curved.

Abstract: Provided are a hormone secretion modulator including a peptide derived from telomerase, more particularly, a peptide including an amino acid sequence of SEQ ID NO: 1, an amino acid sequence having a sequence identity of at least 80% with SEQ ID NO: 1, or a fragment thereof, a pharmaceutical composition including the hormone secretion modulator, and a use of the pharmaceutical composition for treatment, alleviation, or prevention of diseases caused by excessive or deficient levels hormones.

Abstract: The present specification discloses a pharmaceutical composition for preventing or treating ophthalmopathy. More particularly, disclosed is a composition comprising a peptide derived from telomerase and being effective in treating and preventing ophthalmopathy. The disclosed peptide, a peptide having a sequence 80% identical to the sequence thereof, or a peptide as a fragment thereof is superiorly effective in treating ophthalmopathy.

Abstract: A pharmaceutical composition for preventing or treating ophthalmopathy is described. More particularly, a composition comprising a peptide derived from telomerase and being effective in treating and preventing ophthalmopathy is described. The peptide derived from telomerase, a peptide having a sequence 80% identical to the sequence thereof, or a peptide as a fragment thereof is superiorly effective in treating ophthalmopathy.

Abstract: A flexible display device may include a display module including a first non-bending area and a first bending area adjacent to the first non-bending area, and a cushion layer disposed on a rear surface of the display module, wherein the cushion layer has a first density in the first non-bending area and a second density in the first bending area, and the first density is lower than the second density.